Q1 · MEDICINE
Article
Author: Dichiara, Maria ; Santos-Caballero, Miriam ; Rodríguez-Gómez, Isabel ; Turnaturi, Rita ; Barbaraci, Carla ; Gómez-Guzmán, Manuel ; Cobos, Enrique J ; Artacho-Cordón, Antonia ; Pasquinucci, Lorella ; González-Cano, Rafael ; Marrazzo, Agostino ; Amata, Emanuele
The development of σ1 receptor antagonists hybridized with a H2S-donor is here reported. We aimed to obtain improved analgesic effects when compared to σ1 receptor antagonists or H2S-donors alone. In an in vivo model of sensory hypersensitivity, thioamide 1a induced analgesia which was synergistically enhanced when associated with the σ1 receptor antagonist BD-1063. The selective σ1 receptor agonist PRE-084 completely reversed this effect. Four thioamide H2S-σ1 receptor hybrids (5a-8a) and their amide derivatives (5b-8b) were synthesized. Compound 7a (AD164) robustly released H2S and showed selectivity for σ1 receptor over σ2 and opioid receptors. This compound induced marked analgesia that was reversed by PRE-084. The amide analogue 7b (AD163) showed only minimal analgesia. Further studies showed that 7a exhibited negligible acute toxicity, together with a favorable pharmacokinetic profile. To the best of our knowledge, compound 7a is the first dual-acting ligand with simultaneous H2S-release and σ1 antagonistic activities.